Skip to main content

Chronic Lymphocytic Leukemia (CLL) Clinical Trials

Review the chronic lymphocytic leukemia (cll) clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-123 of 123

Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells with Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Patients with Relapsed or Refractory B-cell Hematologic Malignancies
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Florida, Jacksonville, Florida
Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Evaluation of Smartphone Wellness Apps for the Management of Sleep Disturbances in Patients with a Hematological Cancer
Status: Active
Location: 3 locations
Personalized Exercise and Nutrition Programs to Improve Cancer-Related Fatigue in Patients with Indolent Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Status: Active
Location: 3 locations
Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Post-Transplant Cyclophosphamide for the Prevention of Graft Versus Host Disease in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning for Hematological Diseases
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Status: Active
Location: 2 locations
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Predictors of Health-Related Quality of Life in Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Implementation of a Medication Adherence Intervention for Chronic Leukemia Patients (Aim 3)
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma after CAR-T Treatment
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Status: Active
Location: 722 locations
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Status: Active
Location: 7 locations
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients with B-cell Malignancies Undergoing Treatment with Bruton Tyrosine Kinase Inhibitors, the HALT Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Status: Enrolling by Invitation
Location: National Institutes of Health Clinical Center, Bethesda, Maryland